A phase III randomized trial of adults aged 50 years or older demonstrated that coadministration of the respiratory syncytial virus vaccine mRNA-1345 with seasonal influenza or COVID-19 vaccines showed acceptable safety profiles and mostly noninferior immunogenicity. The study revealed no significant safety concerns, and the reactogenicity profiles of the coadministered regimens were generally similar to the profiles when the vaccines were administered alone.